243 related articles for article (PubMed ID: 35400704)
1. Olfactory Dysfunction Reflects Disease Progression in Japanese Patients with Multiple Sclerosis.
Okada K; Kakeda S; Tahara M
Intern Med; 2022 Nov; 61(21):3181-3187. PubMed ID: 35400704
[TBL] [Abstract][Full Text] [Related]
2. Olfactory identification associates with cognitive function and the third ventricle width in patients with relapsing-remitting multiple sclerosis.
Okada K; Kakeda S; Tahara M
Mult Scler Relat Disord; 2020 Feb; 38():101507. PubMed ID: 31766000
[TBL] [Abstract][Full Text] [Related]
3. Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
Kizlaitienė R; Kaubrys G; Giedraitienė N; Ramanauskas N; Dementavičienė J
Med Sci Monit; 2017 Feb; 23():588-597. PubMed ID: 28145395
[TBL] [Abstract][Full Text] [Related]
4. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
[TBL] [Abstract][Full Text] [Related]
5. Thalamic asymmetry in Multiple Sclerosis.
Ramezani N; Davanian F; Naghavi S; Riahi R; Zandieh G; Danesh-Mobarhan S; Ashtari F; Shaygannejad V; Sanayei M; Adibi I
Mult Scler Relat Disord; 2023 Sep; 77():104853. PubMed ID: 37473593
[TBL] [Abstract][Full Text] [Related]
6. Thalamic atrophy correlates with dysfunctional impulsivity in multiple sclerosis.
Joly H; Capet N; Mondot L; Cohen M; Suply C; Bresch S; Lebrun-Frenay C
Mult Scler Relat Disord; 2020 Sep; 44():102374. PubMed ID: 32652509
[TBL] [Abstract][Full Text] [Related]
7. Cortical dysfunction underlies disability in multiple sclerosis.
Vucic S; Burke T; Lenton K; Ramanathan S; Gomes L; Yannikas C; Kiernan MC
Mult Scler; 2012 Apr; 18(4):425-32. PubMed ID: 21965421
[TBL] [Abstract][Full Text] [Related]
8. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS.
Rocca MA; Valsasina P; Meani A; Gobbi C; Zecca C; Rovira À; Montalban X; Kearney H; Ciccarelli O; Matthews L; Palace J; Gallo A; Bisecco A; Gass A; Eisele P; Lukas C; Bellenberg B; Barkhof F; Vrenken H; Preziosa P; Comi G; Filippi M;
Neurology; 2019 Nov; 93(20):e1852-e1866. PubMed ID: 31611336
[TBL] [Abstract][Full Text] [Related]
9. The glymphatic system as a potential biomarker and therapeutic target in secondary progressive multiple sclerosis.
Tomizawa Y; Hagiwara A; Hoshino Y; Nakaya M; Kamagata K; Cossu D; Yokoyama K; Aoki S; Hattori N
Mult Scler Relat Disord; 2024 Mar; 83():105437. PubMed ID: 38244527
[TBL] [Abstract][Full Text] [Related]
10. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z
Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis.
Healy BC; Zurawski J; Chitnis T; Weiner HL; Glanz BI
Qual Life Res; 2022 Jun; 31(6):1799-1805. PubMed ID: 34783972
[TBL] [Abstract][Full Text] [Related]
12. Relapsing-remitting and secondary-progressive multiple sclerosis patients differ in decoding others' emotions by their eyes.
Argento O; Spanò B; Serra L; Incerti CC; Bozzali M; Caltagirone C; Francia A; Fratino M; Nocentini U; Piacentini C; Quartuccio ME; Pisani V
Eur J Neurol; 2022 Feb; 29(2):505-514. PubMed ID: 34687120
[TBL] [Abstract][Full Text] [Related]
13. Continuous diffuse brain atrophy independent of relapse as a hallmark of multiple sclerosis beginning from relapsing-remitting stage.
Akaishi T; Fujimori J; Yokote H; Nakashima I
Clin Neurol Neurosurg; 2024 Jul; 242():108342. PubMed ID: 38772279
[TBL] [Abstract][Full Text] [Related]
14. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
15. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
[TBL] [Abstract][Full Text] [Related]
16. A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.
Ziemssen T; Piani-Meier D; Bennett B; Johnson C; Tinsley K; Trigg A; Hach T; Dahlke F; Tomic D; Tolley C; Freedman MS
J Med Internet Res; 2020 Feb; 22(2):e16932. PubMed ID: 32049062
[TBL] [Abstract][Full Text] [Related]
17. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
Choi IY; Lee P; Adany P; Hughes AJ; Belliston S; Denney DR; Lynch SG
Mult Scler; 2018 Jul; 24(8):1029-1038. PubMed ID: 28569645
[TBL] [Abstract][Full Text] [Related]
18. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
[TBL] [Abstract][Full Text] [Related]
19. Olfactory Dysfunction and Cognition in Radiologically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis.
Arici Duz O; Saatci O; Karakulak EZ; Birday E; Hanoglu L
Eur Neurol; 2021; 84(3):175-182. PubMed ID: 33831865
[TBL] [Abstract][Full Text] [Related]
20. Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.
Kopp TI; Bramow S; Illes Z; Kant M; Kristensen C; Rasmussen PV; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2021 Nov; 56():103319. PubMed ID: 34666241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
